Moderna, Inc. (MRNA) - Stock Analysis

Biotechnology
Healthcare

Moderna, Inc.

MRNA · US · NASDAQ

82.9

USD

+1.61

(1.94%)

-15.28

EPS
-5.43

P/E
31.9B

MARKET CAP
0.00%

DIV YIELD

Company Overview

200 TECHNOLOGY SQUARE,CAMBRIDGE MA 02139,6177146500

CEO

Mr. Stephane Bancel

Employess

5600

Sector

Healthcare

Industry

Biotechnology

Website

https://www.modernatx.com

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Next Earnings Date

Nov. 7, 2024

Ex Dividends date

Dividend Date

YTD Performance

-26.36%

Fiscal Year End

12-31

IPO Date

2018-12-07

Growth Rates

(avg. rate of change)	10 years	5 years	3 years	1 year
Sales/Revenue	%	122.99%	190.86%	-64.94%
EPS	%	-21.09%	-84.65%	-58.15%
Equity	%	55.37%	75.54%	-27.55%
Cash	%	34.58%	3.47%	-9.30%
Return On Capital (ROIC)	%	4.94%	29.33%	-33.58%

Debt

year (millions)	2023	2022	2021	2020	2019
Short Term Debt	25	196	211	470	67.7
Long Term Debt	1,220	1,000	705	207	132
LT Finance Leases	1,240	1,000	916	207	132
Shares Outstanding	382	394	403	381	331
Market Cap	38,000	70,800	102,000	39,800	6,470

Price

Business Segments (Beta)

Geographical Segments (Beta)

News

Moderna, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – MRNA

1 month

NEW YORK, NY / ACCESSWIRE / August 13, 2024 / If you suffered a loss on your Moderna, Inc. (NASDAQ:MRNA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/moderna-lawsuit-submission-form?prid=95456&wire=1 or contact Joseph E. Levi, Esq.

accesswire.com

Moderna Inc Investors Can Take The Lead In Securities Fraud Lawsuit With The Schall Law Firm

1 month

LOS ANGELES, CA / ACCESSWIRE / August 13, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Moderna, Inc. ("Moderna" or "the Company") (NASDAQ: MRNA ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between January 18, 2023 and June 25, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before October 8, 2024.

accesswire.com

Levi & Korsinsky Reminds Moderna, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 8, 2024 - MRNA

1 month

accesswire.com

Investors Who Lost Money on Moderna, Inc. (MRNA) Should Contact Levi & Korsinsky About Pending Class Action - MRNA

1 month

accesswire.com

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Moderna, Inc. of Class Action Lawsuit and Upcoming Deadlines - MRNA

1 month

NEW YORK, NY / ACCESSWIRE / August 13, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against Moderna, Inc. ("Moderna" or the "Company") (NASDAQ:MRNA) and certain officers. The class action, filed in the United States District Court for the District of Massachusetts, and docketed under 24-cv- 12058, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Moderna securities between January 18, 2023 and June 25, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

accesswire.com

3 Biotech Stocks Poised for a Comeback After Last Week's Market Meltdown

1 month

Due to their sometimes speculative nature, biotech stocks are especially sensitive to broader market corrections like the one experienced last week. This can be exceptionally stressful for investors, especially those who bought into biotech stocks at overbought points in the stocks' trading cycle.

investorplace.com

Moderna, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before October 8, 2024 to Discuss Your Rights - MRNA

1 month

accesswire.com

MRNA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Moderna, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

1 month

NEW YORK, NY / ACCESSWIRE / August 13, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Moderna, Inc. ("Moderna" or "the Company") (NASDAQ:MRNA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Moderna securities between January 18, 2023, and June 25, 2024, inclusive (the "Class Period").

accesswire.com

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 8, 2024 in Moderna, Inc. Lawsuit - MRNA

1 month

NEW YORK, NY / ACCESSWIRE / August 12, 2024 / If you suffered a loss on your Moderna, Inc. (NASDAQ:MRNA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/moderna-lawsuit-submission-form?prid=95273&wire=1 or contact Joseph E. Levi, Esq.

accesswire.com

Investors who lost money on Moderna, Inc. (MRNA) should contact Levi & Korsinsky about pending Class Action - MRNA

1 month

accesswire.com

MRNA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Moderna, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

1 month

NEW YORK, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Moderna, Inc. (“Moderna” or “the Company”) (NASDAQ: MRNA) and certain of its officers.

globenewswire.com

Lost Money on Moderna, Inc.(MRNA)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky

1 month

accesswire.com